NuCana (NCNA) Share-based Compensation (2017 - 2025)

NuCana (NCNA) reported Share-based Compensation of $1.2 million for Q4 2025, up 4467.5% on a YoY basis from $25773.3 in Q4 2024, and down 2.63% sequentially from $1.2 million in Q3 2025.

NuCana (NCNA) Share-based Compensation (2017 - 2025) Analysis & Trends

NuCana (NCNA) has 9 years of Share-based Compensation data on file, last reported at $1.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 4467.5% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (up 35.87% YoY), and the FY2025 full-year result was $13.2 million, up 528.41% from the prior year.
  • Share-based Compensation retreated to $1.2 million in Q4 2025, from $1.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q2 2021 to a low of -$26953.5 in Q4 2024.
  • A 5-year average of $1.4 million and a median of $1.3 million in 2025 frame the typical range for Share-based Compensation.
  • Across the five-year window, Share-based Compensation slumped 102.77% in 2024 and jumped 4467.5% in 2025, its largest moves.
  • Tracing NCNA's Share-based Compensation over 5 years: stood at $2.4 million in 2021, then tumbled by 37.58% to $1.5 million in 2022, then plunged by 33.73% to $973063.1 in 2023, then tumbled by 102.77% to -$26953.5 in 2024, then jumped by 4467.5% to $1.2 million in 2025.
  • Business Quant data shows NCNA's Share-based Compensation at $1.2 million in Q4 2025, $1.2 million in Q3 2025, and -$26953.5 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 6.39 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9.26 Mn
4 NuCana 279.75 Bn 279.75 Bn - 1.18 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 166.40 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 257.40 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 87.30 Mn
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.18 Mn
Dec 31, 2025 1.18 Mn
Sep 30, 2025 1.21 Mn
Sep 30, 2025 1.21 Mn
Dec 31, 2024 -26,953.54
Dec 31, 2024 -26,953.54
Sep 30, 2024 487,237.56
Sep 30, 2024 487,237.56
Jun 30, 2024 840,639.02
Jun 30, 2024 840,639.02
Mar 31, 2024 794,092.38
Mar 31, 2024 794,092.38
Dec 31, 2023 973,063.08
Dec 31, 2023 973,063.08
Sep 30, 2023 1.11 Mn
Sep 30, 2023 1.11 Mn
Jun 30, 2023 1.32 Mn
Jun 30, 2023 1.32 Mn
Mar 31, 2023 1.39 Mn
Mar 31, 2023 1.39 Mn